Preview: Summit Therapeutics's Earnings
Preview: Summit Therapeutics's Earnings
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).Summit Therapeutics (NASDAQ:SMMT) is set to give its latest quarterly earnings report on Wednesday, 2024-10-30. Here's what investors need to know before the announcement.
summit therapeutics（納斯達克：SMMT）將在2024年10月30日（星期三）公佈最新的季度業績。投資者在公佈之前需要了解的內容如下。
Analysts estimate that Summit Therapeutics will report an earnings per share (EPS) of $-0.07.
分析師預計，Summit Therapeutics的每股收益（EPS）將爲-0.07美元。
Summit Therapeutics bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
Summit Therapeutics的支持者希望公司宣佈他們不僅超過了這一預期，還提供積極的指引，或者對下個季度的增長進行了預測。
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
新投資者應該注意，有時不是盈利與否影響股票價格最大，而是其提供的指導或預測。
Earnings Track Record
歷史業績追蹤
The company's EPS beat by $0.01 in the last quarter, leading to a 1.47% drop in the share price on the following day.
公司上個季度的每股收益超出0.01美元，導致股票價格在隨後一天下跌了1.47%。
Here's a look at Summit Therapeutics's past performance and the resulting price change:
以下是Summit Therapeutics過去的表現以及隨之而來的價格變化：
| Quarter | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|
| EPS Estimate | -0.06 | |||
| EPS Actual | -0.05 | -0.06 | -0.05 | -0.03 |
| Price Change % | -1.0% | -14.000000000000002% | 10.0% | -5.0% |
| 季度 | 2024年第二季度 | Q1 2024 | 2023年第四季度 | 2023年第三季度 |
|---|---|---|---|---|
| 每股收益預估值 | -0.06 | |||
| 每股收益實際值 | -0.05 | -0.06 | -0.05 | -0.03 |
| 價格變更% | -1.0% | -14.000000000000002% | 10.0% | -5.0％ |
To track all earnings releases for Summit Therapeutics visit their earnings calendar on our site.
要跟蹤summit therapeutics的所有業績，請訪問我們網站上的業績日曆。
This article was generated by Benzinga's automated content engine and reviewed by an editor.
本文由Benzinga的自動化內容引擎生成並由編輯審查。
譯文內容由第三人軟體翻譯。
